The image contains multiple graphs showing tumor growth and treatment effects in different cancer models. Panels A to L display individual tumor growth curves for B 16 F 10 melanoma and D X 1 prostate cancer under various treatments. Panel M shows tumor volumes in mice treated with vehicle or H I F inhibitor, with statistical significance indicated. Panel N presents mR N A analysis results from D X 1 tumors. Panel O shows tumor volume measurements for E 0 771 tumors, with statistical significance noted. Panel P displays final tumor weights for E 0 771 tumors, with statistical comparisons. Panel Q compares tumor volumes in rechallenged versus naive mice. Panel R illustrates the gating strategy for flow cytometry data. Each graph includes axes labeled with days and tumor volume with statistical annotations clearly marked. All data is approximate.
Melanoma, prostate, and breast tumor models. Related to Figs. 6 and 7. (A–L) B16F10 melanoma (A–F) and DX1 prostate cancer (G–L) individual tumor growth curves under indicated treatments are shown. (M) Mice bearing DX1 tumors were treated with vehicle or HIFi (40 mg/kg BID IP) for 5 days. Tumor volumes are presented as the mean ± SD (n = 5); *P < 0.05 versus vehicle by two-way ANOVA with Tukey’s post-test. (N) RNA was isolated from DX1 tumors 4 h after the last treatment and analyzed by RT-qPCR (mean + SD, n = 5). *P < 0.05 by one-way ANOVA with the Bonferroni post-test. (O) E0771 tumor volume measurements are shown (mean + SD, n = 5). **P < 0.01 by two-way ANOVA with Tukey’s post-test. (P) E0771 final tumor weights are presented as the mean ± SD, n = 5. **P < 0.01; ****P < 0.0001; ns by one-way ANOVA with Dunnett’s post-test. (Q) E0771 tumor volumes (mean ± SD) in rechallenged versus naïve mice are shown. (R) Gating strategy for the flow cytometry data presented in Fig. 7, G–L is shown.